Patent intelligence · US
US 9278096
Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Patent details — US 9278096
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 8, 2016
- Expiration
- Mar 3, 2036
- Claims
- 26
- CPC classes
- A61K, A61K31/495, A61P, A61P1/14
Quick answer
US 9278096 (Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity) is held by Takeda Pharmaceuticals North America, Inc.. Status: granted. Granted Mar 8, 2016. Expires Mar 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/495, A61P, A61P1/14, A61P11/00, A61P15/10
More from Takeda Pharmaceuticals North America, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 9278096?
US 9278096 (Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity) is held by Takeda Pharmaceuticals North America, Inc.. Status: granted. Granted Mar 8, 2016. Expires Mar 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9278096?
Takeda Pharmaceuticals North America, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 9278096 expire?
Our index shows an expiration date of Mar 3, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.